-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
HeartSciences to Participate at the Benchmark Discovery One-on-One Investor Conference on December 1, 2022
HeartSciences to Participate at the Benchmark Discovery One-on-One Investor Conference on December 1, 2022
Southlake, Texas, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) ("HeartSciences" or the "Company"), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screening tool through the use of AI, today announced that Andrew Simpson, Chief Executive Officer of HeartSciences, will be participating at the at the 11th Annual Benchmark Discovery One-on-One Investor Conference which is being held on December 1, 2022, at the New York Athletic Club in New York City.
Mr. Simpson will take part in one-on-one meetings with institutional analysts and investors throughout the conference. The conference offers emerging growth and dynamic publicly traded companies access to institutional and individual investors in a unique one-on-one format.
To schedule a one-on-one meeting with Mr. Simpson you may submit your request online via the link provided upon registration. To register for the conference, please visit .
About The Benchmark Company
The Benchmark Company is an institutionally focused, research driven, sales trading and investment banking firm. We were founded in 1988 and are headquartered in New York City. Our focus is on fostering the long-term success of our corporate clients through raising capital, providing strategic advisory services, generating insightful research, and developing institutional sponsorship by leveraging the firm's sales, trading and equity research capabilities. For more information, please visit
About HeartSciences
Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical usefulness. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences' first product candidate for FDA clearance, the MyoVista® wavECG, or the MyoVista®, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista® also provides conventional ECG information in the same test. The business model, which involves the use of the MyoVista® device and consumables for each test, is expected to be "razor-razorblade" as the electrodes used with the MyoVista® are proprietary to HeartSciences, and new electrodes are required for every test performed.
For more information, please visit: Twitter: @HeartSciences
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about HeartSciences' beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences' filings with the U.S. Securities and Exchange Commission at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
For investor and media inquiries, please contact:
Investor Relations:
Crescendo Communications, LLC
Phone: (212) 671-1021
Email: HSCS@crescendo-ir.com
Company:
Gene Gephart
Phone: +1-737-414-9213 (US)
Email: investorrelations@heartsciences.com
Southlake, Texas, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) ("HeartSciences" or the "Company"), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screening tool through the use of AI, today announced that Andrew Simpson, Chief Executive Officer of HeartSciences, will be participating at the at the 11th Annual Benchmark Discovery One-on-One Investor Conference which is being held on December 1, 2022, at the New York Athletic Club in New York City.
德克薩斯州南湖,2022年11月21日(環球通訊社)心臟測試實驗室公司 D/b/a心臟科學(納斯達克:HSC;HSCSW)(“心臟科學”或“公司”),一家專注於通過使用人工智能使心電(也稱為EKG)成為更有價值的篩查工具來拯救生命的醫療技術公司,今天宣佈,HeartSciences首席執行官Andrew Simpson將參加2022年12月1日在紐約體育俱樂部舉行的第11屆年度Benchmark Discovery一對一投資者大會。
Mr. Simpson will take part in one-on-one meetings with institutional analysts and investors throughout the conference. The conference offers emerging growth and dynamic publicly traded companies access to institutional and individual investors in a unique one-on-one format.
在整個會議期間,辛普森將參加與機構分析師和投資者的一對一會議。該會議以獨特的一對一形式為新興的成長型和有活力的上市公司提供了接觸機構和個人投資者的機會。
To schedule a one-on-one meeting with Mr. Simpson you may submit your request online via the link provided upon registration. To register for the conference, please visit .
要安排與辛普森先生的一對一會面,您可以通過註冊時提供的鏈接在線提交您的請求。要註冊參加會議,請訪問.
About The Benchmark Company
關於基準公司
The Benchmark Company is an institutionally focused, research driven, sales trading and investment banking firm. We were founded in 1988 and are headquartered in New York City. Our focus is on fostering the long-term success of our corporate clients through raising capital, providing strategic advisory services, generating insightful research, and developing institutional sponsorship by leveraging the firm's sales, trading and equity research capabilities. For more information, please visit
The Benchmark Company是一家專注於機構、研究驅動、銷售交易和投資銀行業務的公司。我們成立於1988年,總部設在紐約市。我們的重點是通過籌集資金、提供戰略諮詢服務、產生有洞察力的研究,以及通過利用公司的銷售、交易和股票研究能力發展機構贊助來促進我們的企業客户的長期成功。欲瞭解更多信息,請訪問
About HeartSciences
關於心臟科學
Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical usefulness. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences' first product candidate for FDA clearance, the MyoVista® wavECG, or the MyoVista®, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista® also provides conventional ECG information in the same test. The business model, which involves the use of the MyoVista® device and consumables for each test, is expected to be "razor-razorblade" as the electrodes used with the MyoVista® are proprietary to HeartSciences, and new electrodes are required for every test performed.
For more information, please visit: Twitter: @HeartSciences
心臟測試實驗室,Inc.d/b/a HeartSciences是一家醫療技術公司,專注於將基於人工智能的創新技術應用於心電(也稱為EKG),以擴大和提高心電的臨牀用途。該公司的目標是通過使心電成為一種更有價值的心臟篩查工具來改善醫療保健,特別是在一線或護理點臨牀環境中。心臟科學公司的第一款獲得美國食品和藥物管理局批准的產品MyoVista®WaveCG,或稱MyoVista®,是一種靜止的12導聯心電,也是為了提供與心臟功能障礙有關的診斷信息而設計的,傳統上只能通過使用心臟成像來獲得。MyoVista®還可以在同一測試中提供常規的心電信息。商業模式包括使用MyoVista®設備和每項測試的消耗品,預計將是“剃刀刀片”,因為MyoVista®使用的電極是心臟科學公司的專利,每進行一次測試都需要新的電極。
欲瞭解更多信息,請訪問:Twitter:@HeartSciences
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about HeartSciences' beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences' filings with the U.S. Securities and Exchange Commission at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
安全港聲明
本公告包含符合1933年《證券法》第27A節和1934年《證券交易法》第21E節的前瞻性陳述。這些前瞻性陳述是根據“1995年私人證券訴訟改革法”中的“安全港”條款作出的,與公司未來的財務和經營業績有關。除對歷史事實的陳述外,本文中包括的所有陳述都是“前瞻性陳述”,其中包括關於心臟科學公司的信念和期望的陳述。這些陳述基於目前的預期、假設和不確定性,這些不確定性涉及對未來經濟、競爭和市場狀況以及未來商業決策的判斷,所有這些都很難或不可能準確預測,而且許多都不是公司所能控制的。這些前瞻性陳述中反映的預期涉及重大假設、風險和不確定因素,這些預期可能被證明是不正確的。投資者不應過分依賴這些前瞻性陳述,這些陳述僅反映了本新聞稿發佈之日的情況。潛在的風險和不確定因素包括但不限於心臟科學公司在提交給美國證券交易委員會的文件中討論的風險,這些文件的網址是www.sec.gov。除證券法規定外,公司不承擔更新這些前瞻性陳述的責任。
For investor and media inquiries, please contact:
Investor Relations:
Crescendo Communications, LLC
Phone: (212) 671-1021
Email: HSCS@crescendo-ir.com
投資者和媒體查詢,請聯繫:
投資者關係:
Cresendo Communications,LLC
電話:(212)671-1021
電子郵件:hscs@cresendo-ir.com
Company:
Gene Gephart
Phone: +1-737-414-9213 (US)
Email: investorrelations@heartsciences.com
公司:
吉恩·格法特
電話:+1-737-414-9213(美國)
電子郵件:郵箱:Investorrelations.com
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧